Canadian ciprofloxacin susceptibility study: Comparative study from 15 medical centers

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1729-1732

  Blondeau, J M ^a,b   Yaschuk, Y ^a   Smith, J A ^c   Noble, M A ^d   Kibsey, P ^e   Horsman, G B ^f   Hoban, D J ^g   Colby, W D ^h   Jessamine, P ⁱ   Simor, A E ^j   Low, D E ^k   Bourgault, A M ^l   Laverdiere, M ^m   Kuhn, M ⁿ   MacDonald, S ^o   Brown, W ^p  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Health Region St Pauls Hospital   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e GREY NUNS COMMUNITY HOSPITAL   (Canada)

^f H E Robertson Laboratory   (Canada)

^g HEALTH SCIENCES CENTRE   (Canada)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^k MOUNT SINAI HOSPITAL   (Canada)

^l UNIVERSITY OF MONTREAL   (Canada)

^m MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁿ MONCTON HOSPITAL   (Canada)

^o QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^p Health Sciences Centre St John's   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFAMANDOLE; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; NETILMICIN; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CANADA; ENTEROBACTERIACEAE; HAEMOPHILUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 8944262186     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1729     Document Type: Article

References (14)

1. Chamberland, S., J. L'Ecuyer, C. Lessard, M. Bernier, P. Provencher, M. Bergeron, and the Canadian Study Group. 1992. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolates from septicemic patients throughout Canada. Clin. Infect. Dis. 15:615-628.
2. Committee on Antimicrobial Agents, Canadian Infectious Diseases Society, and T. J. Louie. 1994. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Can. Med. Assoc. J. 150:669-676.
3. Coronado, V. G., J. R. Edwards, D. H. Culver, R. P. Gaynes, and The National Nosocomial Infections Surveillance (NNIS) System. 1995. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect. Control Hosp. Epidemiol. 16: 71-75.
4. Felmingham, D., M. D. O'Hare, M. J. Robbins, R. A. Wall, A. H. Williams, A. W. Cremer, G. L. Ridgway, and R. N. Gruneberg. 1985. Comparative in vitro studies with 4-quinolone antimicrobials. Drugs Exp. Clin. Res. XI:317-329.
5. Hoban, D. J., and R. N. Jones. 1993. The North American component (USA, Canada) of an international comparative MIC trial monitoring ofloxacin resistance. Drugs 45(Suppl. 3):167-169.
6. Hoban, D. J., R. N. Jones, and The Canadian Ofloxacin Study Group. 1995. Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Chemotherapy 41:34-38.
7. National Committee for Clinical Laboratory Standards. 1993. Approved standard M7-A2. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. National Committee for Clinical Laboratory Standards. Villanova, Pa.
8. Parry, M. F., K. B. Panzer, and M. E. Yukna. 1989. Quinolone resistance: susceptibility data from a 300-bed community hospital. Am. J. Med. 87(Suppl. 5A):12S-16S.
9. Raviglione, M. C., J. F. Boyle, P. Mariuz, A. Pablos-Mendez, H. Cortes, and A. Merlo. 1990. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob. Agents Chemother. 34:2050-2054.
10. Shalit, I., S. A. Berger, A. Gorea, and H. Frimerman. 1989. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob. Agents Chemother. 33:593-594.
11. Tillotson, G., K. Culshaw, and B. O'Keeffe. 1994. Gram-negative bacterial susceptibility to ciprofloxacin - a six year UK perspective, abstr. 136. In Abstracts of the 6th International Congress on Infectious Diseases.
12. Toye, B. W., S. R. Scriver, D. E. Low, and The Canadian Antimicrobial Resistance Study Group. 1993. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J. Antimicrob. Chemother. 32(Suppl. B):81-86.
13. Walker, R. C., and A. J. Wright. 1991. The fluoroquinolones. Mayo. Clin. Proc. 66:1249-1259.
14. Wiedeman, B., and M. T. Zuhlsdorf. 1989. Brief report: resistance development to fluoroquinolones in Europe. Am. J. Med. 87(Suppl. 5A):9S-11S.